This review summarizes available evidence for the rationale for vWF inhibition in ischaemic stroke in the light of disadvantages of currently used pharmacotherapy, suggests how these may be addressed by targeting the GPIb-vWF axis and discusses stroke populations that may benefit from vWF-targeted therapy. This evidence concerns the gene VWF and ischemic stroke.